Introduction
============

Bronchodilators are first line treatment for chronic obstructive pulmonary disease (COPD) and have been shown to improve lung function, decrease exacerbation frequency and rescue medication use and patient symptoms, including dyspnea and health status ([@b33-copd-3-385]; [@b5-copd-3-385]). Bronchodilators may act as anticholinergic agents (eg, ipratropium bromide or tiotropium) or as beta2-agonists. The beta-agonists are divided into short-acting (SABA) and long-acting (LABA) forms. The LABA have two principal forms: salmeterol and formoterol.

Formoterol has been used for over 10 years, initially to treat asthmatic subjects. Recent publications have highlighted the potential use of formoterol, in combination with budesonide, as a single inhaled preparation for the treatment of asthma ([@b41-copd-3-385]; [@b45-copd-3-385]). Arformoterol is the (R,R) enantiomer of formoterol ([@b56-copd-3-385]; [@b23-copd-3-385]). Preclinical studies have suggested that arformoterol is a more potent beta2-agonist than formoterol. Arformoterol is the only LABA available as in an inhalational solution for use in a nebulizer ([@b10-copd-3-385]).

This review will assess the different pharmacology/modes of action and clinical efficacy of arformoterol in comparison with other long-acting beta2-agonists.

Pharmacology
============

All beta2-agonists bind to beta2-adrenoceptors on bronchial smooth muscle. The amount of bronchodilator response is related to the concentration of the drug in the vicinity of the smooth muscle (except for salmeterol which is aliphatic) and the degree of beta2-adrenoceptor activation. The long-acting beta2-agonists were first used in the 1980s ([@b28-copd-3-385]). Salmeterol is a partial agonist at the beta2-adrenoceptor achieving maximum effect after 60 minutes ([@b14-copd-3-385]), whilst formoterol is a full agonist, achieving a more rapid onset of action with significant bronchodilator effect at 5 minutes, similar to short-acting beta2-agonists such as salbutamol ([@b9-copd-3-385]). Both drugs have durations of effect exceeding 12 hours and are recommended for regular use at 12 hourly intervals. Salmeterol and formoterol have differences in their chemical structures ([@b31-copd-3-385]). Formoterol has an additional methoxy group in the side chain which enhances signal transduction ([@b34-copd-3-385]; [@b48-copd-3-385]) when compared with salmeterol (accounting for the partial agonist effect). It has been suggested that the lipophicity of LABAs may allow access to the beta2-adrenoceptors for a prolonged period accounting for their duration of action ([@b4-copd-3-385]).

Formoterol has been shown to have other effects on the airway apart from bronchodilatation. Formoterol inhibits plasma leakage in the airways through the beta2-receptor on the endothelial cells of post-capillary venules ([@b54-copd-3-385]; [@b6-copd-3-385]) and sputum α-2 macroglobulin ([@b22-copd-3-385]). Beta2-agonists including formoterol inhibit mediator release by mast cells, an important benefit in the treatment of asthma ([@b40-copd-3-385]; [@b29-copd-3-385]). Neutrophils have been demonstrated to be a key inflammatory cell in COPD ([@b8-copd-3-385]). Beta2-adrenoceptors are expressed on human neutrophils and beta2-agonists inhibit the release of reactive oxygen species ([@b39-copd-3-385]; [@b37-copd-3-385]). Other studies have demonstrated that LABAs decrease bronchial neutrophils ([@b27-copd-3-385]; [@b35-copd-3-385]).

Enantiomers of formoterol
=========================

Beta2-agonists used as bronchodilators have been formulated as racemates that comprise 50:50 mixtures of (R,R) and (S,S)-enantiomers ([@b23-copd-3-385]). Compounds that are beta2-selective derive their bronchodilator effect from an interaction between the (R,R)-enantiomer and the beta2-adrenoceptor ([@b58-copd-3-385]). Formoterol is a (R,R/S,S) diasteriomer whilst arformoterol is a (R,R)-enantiomer. The (S,S)-enantiomer of formoterol may inhibit airway relaxation. The minimum lethal intravenous dose has been determined to be 100 mg/kg for (R,R)- and 50 mg/kg for (S,S)-formoterol suggesting that the toxicity of (S,S)-formoterol may not be related to the binding of the beta2-adrenoceptor ([@b23-copd-3-385]). These studies suggest that the arformoterol (R,R)-enantiomer) may be more efficacious bronchodilator than formoterol (\[R,R/S,S\] diasteriomer). However, a study that assessed the (R,R), (S,S) and (R,S) found no difference in bronchodilator effect between (R,R)-formoterol and (R,S)-formoterol ([@b50-copd-3-385]). In contrast, another study found in sensitized guinea pigs that (R,R)-formoterol inhibited histamine and antigen-induced bronchoconstriction more than the racemate ([@b23-copd-3-385]).

Some studies have shown that beta2-agonists worsen asthma control by increasing airway inflammation ([@b18-copd-3-385]). This effect may be influenced by different enantiomers, with the (R,R)-enantiomer being anti-inflammatory, and the (S,S)-enantiomer being proinflammatory. The (S,S)-enantiomer of albuterol mediates proinflammatory effects on T cells by interfering with the anti-inflammatory effect of (R,R)-albuterol ([@b7-copd-3-385]). The 2 different enantiomers of formoterol have also been shown to have different effects on inflammatory mediators; (R,R)-formoterol reduces levels of the inflammatory cytokine granulocyte macrophage-colony stimulating factor (GM-CSF) in human airway smooth muscle cells whilst (S,S)-formoterol increased levels of GM-CSF ([@b3-copd-3-385]) and levels of IL-4 in mast cells in a murine asthma model ([@b2-copd-3-385]). Beta2-agonists interact with specific receptors on the surface of T lymphocytes ([@b47-copd-3-385]). Steinke et al assessed the effect of different formoterol enantiomers on T cell function in 10 healthy human controls ([@b53-copd-3-385]). This study found that the (R,R) formoterol had predominantly anti-inflammatory effects on T cell function (proliferation and cytokine production) whilst the racemate had opposite effects. There appears to be no in vivo evidence about the different anti-inflammatory effects of racemates in the literature.

Clinical efficacy
=================

Formoterol for the treatment of COPD
------------------------------------

The introduction of the long acting beta2-agonists has been shown to be effective in COPD ([@b46-copd-3-385]). Formoterol, with its unique properties of acute onset and prolonged bronchodilation effect, is potentially both a first-line reliever medication in addition to being maintenance therapy. The use of formoterol in COPD has been recently reviewed ([@b12-copd-3-385]). Four randomized placebo-controlled trails of the use of formoterol in COPD have demonstrated and peak expiratory flow improved lung function (FEV~1~ rates) and symptoms (symptom score and exacerbations) and decreased need for rescue medication ([@b19-copd-3-385]; [@b1-copd-3-385]; Rossi et al 2002; [@b16-copd-3-385]). Anticholinergic agents may reduce severe exacerbations and mortality in COPD when compared with beta2-agonists ([@b49-copd-3-385]).

Arformoterol for the treatment of COPD
--------------------------------------

There have been two studies (published/in press) in journals assessing the effect of arformoterol in COPD ([@b10-copd-3-385]; [@b26-copd-3-385]). These were two identical, 12-week, double-blind randomized trials. Subjects were randomized to receive placebo, nebulized arformoterol (15 μg twice daily, 25 μg twice daily, 50 μg daily, and salmeterol metered dose inhahler (MDI) (42 μg twice daily). Subjects were followed up for 12 weeks and the percentage average change in trough FEV~1~, percentage change in FEV~1~ from AUC (0--12 hours), and peak percentage change FEV~1~ predose were analyzed. A total of more than 1400 subjects completed the trials, and similar results were obtained from both trials. The pooled data from these studies showed that the median time to achieve a 10% improvement in FEV~1~ from predose levels at week 12 was 3--13 minutes with nebulised arformoterol, and 142 minutes with salmeterol. Arformoterol 25 μg given twice daily was more effective than arformoterol 50 μg daily (percentage change in trough FEV~1~: 17.8% and 15.3%) but arformoterol 50 μg daily was similar to salmeterol 42 μg twice daily. After 12 weeks the 78%--87% of arformoterol subjects had ≥10% increase in compared with 56% salmeterol and 44% placebo. The FEV~1~ results of these 2 large trials demonstrate that arformoterol is effective in improving lung function in COPD, perhaps more so than salmeterol. The major criticism of these trials is in the selection of the COPD subjects. The patients were selected as having physician diagnosed nonasthmatic COPD. Subjects had all had a \> than 15 pack-year smoking history with the average being \>60 years and the mean FEV~1~ of the group was 41% predicted. However, the mean airway reversibility of the group was 18.5% at randomization, suggesting that at least some subjects may have had coexistent asthma. Nonetheless, as lung volumes were low (baseline FEV~1~ of 0.7 L), an 18.5% airway reversibility may not have been a definite criteria for asthma. There is no detail in this study as to how asthmatic subjects were excluded or whether the initial airway reversibility influenced trial outcomes. It would also have been of interest to have a racemic formoterol arm in the trial.

Several studies of the clinical efficacy of arformoterol have been presented at conferences and data are available in conference abstracts. An open label, randomized crossover study of arformoterol (15 μg) and racemic formoterol (12 μg and 24 μg) in 39 COPD subjects found similar improvements in lung function with all 3 doses ([@b24-copd-3-385]). A crossover dose-ranging study in which COPD subjects received arformoterol at 9.6 μg 4 times daily, 24 μg twice daily, 48μg 4 times daily or 96 μg twice daily compared with placebo found that all doses significantly improved FEV~1~ and there was no added benefit to having a dose higher than 24 μg twice daily ([@b11-copd-3-385]). An analysis of patient-centered outcomes in the two trials of 1456 COPD found patients experienced similar improvements in dyspnea, overall self reported functioning and decreased rescue medication for both arformoterol and salmeterol versus placebo ([@b24-copd-3-385]). A 12 month trial was conducted to assess the effect of once daily arformoterol at a dose of 50 μg in 528 patients with COPD compared to a control group of 285 patients with COPD who were treated with salmeterol 42 μg twice daily ([@b42-copd-3-385]). This study found that there was a decrease in rescue and supplemental medication with both forms of LABA and over the 12-month period (arfor-both improved trough FEV~1~ moterol more so than salmeterol).

Safety profile of arformoterol
------------------------------

The activation of the beta2-adrenoceptor may cause other effects in addition to bronchodilation including tachycardia, tremor, hypotension, hypokalaemia and hyperglycaemia ([@b44-copd-3-385]). Despite these potential adverse reactions, beta2-agonists have been used successfully in most patients. The TORCH study found that salmeterol had no increase in mortality over a 3-year period compared with placebo ([@b15-copd-3-385]).

As there are significantly fewer clinical data available on the use of arformoterol, the safety of this nebulized drug has not been as clearly established as that of racemic formoterol. In 2 clinical trials of 1400 patients over a 12-week period, arformoterol was well tolerated ([@b11-copd-3-385]; [@b26-copd-3-385]). For patients receiving arformoterol 15 μg bid and 25 μg bid, there was no increase in adverse events compared with placebo. In subjects receiving 50 μg daily of arformoterol there was a 3% increase in mild adverse events compared to control. There were no major adverse events reported. A study that assessed the use of racemic formoterol and arformoterol in asthma found both forms were well tolerated ([@b32-copd-3-385]).

Several other studies have been reported in abstract form. The effect of arformoterol on the QT interval of 215 patients with COPD was studied ([@b10-copd-3-385]). A randomized double-blind trial was used to assess the effects of arformoterol given daily or twice daily (dose from 10 to 50 μg) and found there was no evidence of prolonging of cardiac depolarization. A 12 month trial was conducted to assess the effect of once daily arformoterol at a dose of 50 μg in 528 patients with COPD, compared with a control group of 285 patients with COPD who were treated with salmeterol 42 μg twice daily. The trial found both groups tolerated the medications well, and there was no change in heart rate ([@b42-copd-3-385]).

Tolerance to long acting beta2-agonists has been described to nonspecific challenges ([@b17-copd-3-385]), exercise ([@b51-copd-3-385]; [@b38-copd-3-385]) and allergen ([@b21-copd-3-385]). The clinical significance of tolerance is uncertain and seems to be confined to the early weeks of treatment ([@b30-copd-3-385]) and some bronchoprotection is maintained during long-term treatment ([@b20-copd-3-385]). The bronchodilator response to racemic formoterol shows a small reduction during the initiation of treatment due to the rapid development of tolerance, but this does not progress ([@b59-copd-3-385]). A mild tolerance effect developed to arformoterol over a 12-week period ([@b26-copd-3-385]).

Administration of arformoterol
------------------------------

Arformoterol can only be given by nebulizer, and is not approved by the Federal Drug Administration (FDA) for the treatment of acute exacerbations/rescue therapy. This does significantly restrict the use of this medication; probably mainly to patients who are unable or unwilling to use a dry powder inhalation (DPI) or metered dose inhaler (MDI) preparation of a LABA. Other potential groups who may use nebulized medication are 1) patients who have repeated episodes of airflow obstruction despite DPI/MDI use and 2) patients with severe lung function compromise ([@b43-copd-3-385]).

New beta2-agonists are being developed: the ultra-long acting beta2-agonists, which can be given once a day, and this potential use has been reviewed recently ([@b36-copd-3-385]). A clinical study of arformoterol in asthmatic subjects described 24-hour duration of bronchodilator effect at higher doses ([@b57-copd-3-385]). A subsequent study comparing arformoterol and racemic formoterol found with both drugs that bronchodilation was maintained beyond 12 hours with no significant differences between the two medications ([@b32-copd-3-385]). Several clinical studies of arformoterol have used a once daily dose of 50 μg with effective bronchodilation; this potential of the prolonged action of arformoterol was not discussed in these trials ([@b42-copd-3-385]; [@b26-copd-3-385]).

One potential use of arformoterol may be for the treatment of exacerbations of COPD. Its anti-inflammatory properties may be beneficial in addition to its bronchodilator effects for exacerbations. However, there are no clinical trial data about this, nor has its use been approved for this indication.

Many patients with COPD are treated with combined therapies. A recent study found that arformoterol was compatible with 3 other nebulized drugs: ipratoprium bromide, acetylcysteine and budesonide ([@b13-copd-3-385]). This study did not assess the bronchodilator effects. Combining arformoterol with other inhaled medication may have benefits for some patients. The combination of long acting agents to produce a once daily inhaled medication may have significant benefits ([@b36-copd-3-385]).

Conclusion
==========

Arformoterol is a newly developed long acting beta2-agonist given by nebulizer that has been approved for the maintenance treatment of COPD in the US. Arformoterol is the (R,R)-enantiomer of formoterol. There is a relative lack of published data about this medication. Being a (R,R)-enantiomer it may have more potent bronchodilator and anti-inflammatory properties than racemic (R,R/S,S)-formoterol. The clinical trials on the use of arformoterol, while limited in number, have generally been randomized and double-blinded with large numbers of subjects. The results have shown that arformoterol is a safe and effective bronchodilator in COPD, but these results should be interpreted in the light of a high incidence of significant baseline airway reversibility in trial subjects. There does not appear to be are any major clinical differences between arformoterol and racemic-formoterol. The use of arformoterol is restricted by the requirement for nebulization. With its anti-inflammatory properties, arformoterol may have a role in the treatment of exacerbations of COPD.
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###### 

Pharmacological effect of different isomers of formoterol

  Effect                             (R,R)-isomer   (R,S)-isomer   (S,S)-isomer
  ---------------------------------- -------------- -------------- --------------
  Bronchodilation                    ↑ ↑ ↑          ↑ ↑            --
  Duration of BD                     12--24 hours   \>12 hours     --
  Effect on inflammatory mediators                                 
   IL-4                              ↓              --             ↑
   GM-CSF                            ↓              ↑              ↑
   IL-2                              ↓              ↑              --
   IFN-γ                             \-             --             ↑
   IL-13                             ↓              ↑              --
   IL-5                              ↓              ↑              --
  Fas ligand                         ↑              ↓              --

After [@b47-copd-3-385];Armedes et al 2001; [@b7-copd-3-385]; [@b2-copd-3-385]; [@b53-copd-3-385].

**Note:** The (R,R)-isomer is arformoterol and the (R,S)-isomer is racemic formoterol.

**Abbreviations:** BD, bronchodilation; IL, interleukin; FN-γ, interferon gamma; ↓, decreased; ↑, increased; -, no change.

###### 

Clinical efficacy of arformoterol

  Study                                Numbers                    Study design (patients)                        Therapy and duration                                        Findings
  ------------------------------------ -------------------------- ---------------------------------------------- ----------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------
  [@b10-copd-3-385] Hanranhan (2007)   1456 (2 combined trials)   Randomized, placebo controlled, double-blind   Arformoterol, (30--50 μg) and salmeterol (84 μg) 12 weeks   Improvement in FEV~1~, 78%--87% of arformoterol and 44% of salmeterol group had \>10% improvement FEV~1~, improved symptoms and ↓ rescue medication for both
  [@b24-copd-3-385]                    39                         Randomized, cross-over open-label              Arformoterol (15μg), formoterol (12 and 24 μg)              Improvement in FEV~1~, similar with all doses
  Barmgartner (2006)                                              Crossover, dose-ranging                        Arfromoterol (38--192 μg)                                   All dose ↑ no benefit FEV~1~ extra benefit above 48 μg
  [@b42-copd-3-385]                    813                        Randomized, double-blind                       Arformoterol (50μg), salmeterol (84 μg) (12 months)         Improvement in FEV~1~, more with arformoterol and ↓ rescue medication for both

###### 

Clinical safety of arformoterol

  Study               Numbers               Study design (patients)                       Therapy and duration                                    Findings
  ------------------- --------------------- --------------------------------------------- ------------------------------------------------------- -----------------------------------------------------------------------------------
  [@b10-copd-3-385]   1456                  Randomized,                                   Arformoterol                                            Well tolerated,
  [@b24-copd-3-385]   (2 combined trials)   placebo-controlled, double-blind              (30--50 μg) and salmeterol (84 μg) 12 weeks             no changes compared to placebo in side effects, no cardiac issues, Mild tolerance
  [@b32-copd-3-385]   40                    Randomized, double-blind Placebo-controlled   Arformoterol (2--18 μg) racemic formoterol (4--36 μg)   Well tolerated, no difference in medications
  [@b10-copd-3-385]   215                   Randomized, Double-blind                      Arformoterol (10--50 μg)                                No effect on cardiac depolarization
  [@b42-copd-3-385]   813                   Randomized, double-blind (12 months)          Arformoterol (50 μg), salmeterol (84 μg)                Well tolerated no change in heart rate
